Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis & Investment Frameworks
Tarsus Pharmaceuticals, Inc. (TARS) stock analysis on Invetso. Review Tarsus Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Tarsus Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Tarsus Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $3.37B
- Revenue: $451.36M
- ROE: -13.53%
- ROIC: -11.15%
- Dividend Yield: N/A
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Tarsus Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Tarsus Pharmaceuticals, Inc. (TARS) across the following frameworks:
- Tarsus Pharmaceuticals, Inc. 10Y Growth Potential
- Tarsus Pharmaceuticals, Inc. Scenario Analysis
- Tarsus Pharmaceuticals, Inc. Risks & Opportunities
- Tarsus Pharmaceuticals, Inc. Economic Moat
- Tarsus Pharmaceuticals, Inc. Business Model
- Tarsus Pharmaceuticals, Inc. Management
- Tarsus Pharmaceuticals, Inc. SWOT Analysis
- Tarsus Pharmaceuticals, Inc. Porter's 5 Forces
- Tarsus Pharmaceuticals, Inc. PESTLE Analysis
- Tarsus Pharmaceuticals, Inc. ESG Analysis